Nancy Pryer, PhD, has contributed to discovery and development of eight marketed drugs. She joined Ambagon from DayOne Therapeutics, where she was founding CSO. Prior to DayOne, Nancy was Chief Development Officer at Nurix Therapeutics, a leader in discovering and developing novel drugs that modulate the ubiquitin proteasome system. There, she was responsible for Preclinical and Clinical Development functions and a member of the executive leadership team. Nancy previously served as Vice President of Translational Sciences at BioMarin Pharmaceutical, where she led the company’s efforts in biomarker discovery, bioanalytics, immunogenicity assessment and clinical pharmacology. Prior to BioMarin, she held leadership roles in oncology drug discovery and translational development at Novartis Institutes for Biomedical Research, Raven, SUGEN and Onyx Pharmaceuticals. Nancy earned her PhD in biology from the University of North Carolina, Chapel Hill, and completed post-doctoral work in the lab of Dr. Randy Schekman at the University of California, Berkeley.